Research programme: anti-HAAH monoclonal antibodies - Panacea

Drug Profile

Research programme: anti-HAAH monoclonal antibodies - Panacea

Alternative Names: PAN 22; PAN-355; PAN-622

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Goodwin Biotechnology; Massachusetts Institute of Technology; Panacea Pharmaceuticals
  • Class Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action Aspartic acid 2-oxoglutarate-dependent dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer
  • No development reported Liver cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
  • 01 Apr 2017 Panacea Pharmaceuticals presented pharmacodynamics data from in vitro studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top